Department of Orthopaedic Surgery, Hospital of the University of Pennsylvania, Silverstein-2, 3400 Spruce Street, Philadelphia, PA 19104, USA.
J Bone Joint Surg Am. 2010 Mar;92(3):686-91. doi: 10.2106/JBJS.I.00705.
Fibrodysplasia ossificans progressiva, a rare genetic disorder of progressive extraskeletal ossification, is the most disabling form of heterotopic ossification in humans. However, little is known about the lifespan or causes of mortality in these patients. We undertook this study to determine the lifespan and causes of mortality in individuals who had fibrodysplasia ossificans progressiva.
We reviewed comprehensive mortality reports from two large registries of patients with fibrodysplasia ossificans progressiva. Together, these registries comprise >90% of all known patients with this condition in the world. We noted the sex, dates of birth and death, and the cause of death for each individual. We verified the cause of death with extensive medical records, when available. We also collected date of birth, current age, and sex information for each living patient member of the International Fibrodysplasia Ossificans Progressiva Association.
Sixty deaths (thirty male and thirty female patients) were reported in the fibrodysplasia ossificans progressiva community during a thirty-three-year-period. For all sixty patients, the median age at the time of death was forty years (range, three to seventy-seven years). Data were sufficient to establish the cause of death in forty-eight (80%) of the sixty individuals. The median age at the time of death for the forty-eight patients (twenty-four male and twenty-four female patients) with an established cause of death was also forty years. The median lifespan estimated from the 371 individuals in the international fibrodysplasia ossificans progressiva community who were alive and the sixty who had died was fifty-six years (95% confidence interval, fifty-one to sixty years). The most common causes of death in patients with fibrodysplasia ossificans progressiva were cardiorespiratory failure from thoracic insufficiency syndrome (54%; median age, forty-two years) and pneumonia (15%; median age, forty years).
Fibrodysplasia ossificans progressiva is not only an extremely disabling disease but also a condition of considerably shortened lifespan. The most common cause of death in patients with fibrodysplasia ossificans progressiva is cardiorespiratory failure from thoracic insufficiency syndrome.
纤维性骨发育不良进行性骨化,一种罕见的进行性外骨骼骨化遗传疾病,是人类异位骨化中最致残的形式。然而,对于这些患者的寿命或死亡原因知之甚少。我们进行这项研究是为了确定纤维性骨发育不良进行性骨化患者的寿命和死亡原因。
我们回顾了两个大型纤维性骨发育不良进行性骨化患者登记处的全面死亡率报告。这两个登记处一起构成了世界上已知患有这种疾病的所有患者的 90%以上。我们记录了每个人的性别、出生日期和死亡日期以及死亡原因。在有可用的情况下,我们通过广泛的医疗记录来验证死亡原因。我们还收集了国际纤维性骨发育不良进行性骨化协会每位在世患者成员的出生日期、当前年龄和性别信息。
在三十年的时间里,纤维性骨发育不良进行性骨化社区报告了六十例死亡(三十名男性和三十名女性患者)。对于所有六十名患者,死亡时的中位年龄为四十岁(范围,三至七十七岁)。在六十名患者中有足够的数据确定了四十八名(80%)的死亡原因。在确定了死因的四十八名患者(二十四名男性和二十四名女性患者)中,死亡时的中位年龄也为四十岁。从国际纤维性骨发育不良进行性骨化协会中存活的 371 名患者和死亡的 60 名患者中估计的中位寿命为五十六年(95%置信区间,五十至六十岁)。纤维性骨发育不良进行性骨化患者死亡的最常见原因是胸壁缺陷综合征引起的心肺衰竭(54%;中位年龄为四十二岁)和肺炎(15%;中位年龄为四十岁)。
纤维性骨发育不良进行性骨化不仅是一种极其致残的疾病,而且寿命也大大缩短。纤维性骨发育不良进行性骨化患者死亡的最常见原因是胸壁缺陷综合征引起的心肺衰竭。